0:03 Can you hear me? Okay, great.
0:09 Right. So, hi everyone. Uh, this
0:10 afternoon I'll be talking to you about
0:13 our verified platform which will help
0:16 with um effectively bringing us closer
0:18 to evidence-based uh antibiotic
0:21 prescribing. As a starting point, a
0:22 little bit about us at Floretic. We're a
0:24 spin out of the University of Bristol.
0:26 Um and our focus is on the grow
0:29 development of rapid growth-free point
0:32 of care tests for effective diagnosis of
0:34 bacterial infections. We've got a
0:37 growing IP portfolio and recognition
0:39 from um various bodies. But probably
0:41 what we're most proud about is that
0:43 we've developed this technology like the
0:46 business from the ground up.
0:48 In terms of our team, we've got a
0:51 assembler team with uh research,
0:52 development, and commercialization
0:55 experience. And um we're still proudly
0:57 founder led led. I'm one of three
1:00 founders of the business and we are well
1:01 supported by a group of industry professionals.
1:04 professionals.
1:06 So we've been known for the last few
1:09 years as a UTI focused company and the
1:10 problem as it sits within the veterary
1:14 context is that data shows 14% of dogs
1:18 and up to 45% of older cats will get UTI
1:20 at some point. And the key challenge for
1:23 vets is can I get this pet on the right
1:25 antibiotic prescription or the right
1:28 antibiotic before the infection becomes
1:31 either persistent or untreatable. And
1:34 the key reason for that is getting from
1:36 symptom to the right treatment today you
1:39 need to go for a multi-day lab test.
1:42 What's really needed actually is a test
1:44 that allows the vets to match the
1:46 infection to the right treatment in the
1:48 first consultation. And I think the
1:50 previous speaker mentioned that and
1:53 that's exactly what we do. So our
1:56 verified platform enables the
1:58 identification of the the causitive
2:00 pathogen within just 15 minutes direct
2:02 from sample. And our sci-fi platform
2:04 does the antibiotic susceptibility test
2:07 within just 30 minutes as well. And
2:09 what's unique about these platforms is
2:10 that they achieve this. They're
2:12 phenotypic, but they achieve this
2:14 without the need to grow bacteria, which
2:16 makes them scalable to multiple types of
2:18 infection. So, today I'll talk mostly
2:21 about our verify platform. Um, and
2:23 verify vet will be our first product.
2:25 That's the MVP version of it, not the
2:28 production one. And it's a 15-minute um
2:30 UTI test direct from sample. And it's
2:32 based on our Nanoplex technology
2:35 platform. So,
2:37 I knew the music was going to come.
2:44 There we go. Just in case you were
2:47 falling asleep. So, um,
2:49 effectively the way it works is it uses
2:52 functionalized uh, latex beads. So, glycans,
2:53 glycans,
2:55 um, synthetic glycans mimic the
2:57 interaction between bacteria and
3:00 epithelial tissue. And so, by having a
3:01 library of glycans, we can target
3:04 different types of bacteria direct from
3:05 sample. And in the process what happens
3:08 is our probes get introduced to the
3:10 sample and they attach kind of like
3:12 velcro forming these structures that you
3:14 see on the left. So where the target
3:16 species is present you get these
3:18 lomerates or clusters that are analyzed
3:20 using computer vision and therefore
3:22 allow us to be able to identify and
3:25 quantify the bacteria in the sample. The
3:26 workflow itself is pretty
3:28 straightforward. um so much so that
3:31 we've enabled we've trained um vet care
3:32 assistants to be able to do it
3:34 reproducibly and we're quite proud of
3:37 that. And now I'm just going to share
3:40 with you um a bit of an output from our
3:42 collaboration with CVS and Axiom Labs.
3:44 So earlier in the year we collected
3:47 samples from cats and dogs urine samples
3:50 and tested those um for the most common
3:53 pathogens and this data was also present
3:55 presented at ECVIM in Mastri. So if
3:57 you're there, apologies, you're hearing
4:01 the talk twice. So the protocol, the
4:04 sensitivity protocol involves 69
4:05 isolates. And we say isolates because
4:07 those samples had to be tested at the
4:10 lab first. And in order to maintain the
4:11 integrity of the pathogen, they were
4:13 plated and then sent to us and then
4:16 reconstituted in urine for us to test.
4:19 So the key pathogens were E.coli,
4:21 Klepsiali, Proteius Morabilis. And as
4:23 you can see in terms of the split
4:26 between canine and feline, 3/4ers of the
4:28 samples were actually canine. And they
4:30 were collected across a range of
4:31 sampling techniques. And that's really
4:33 important because that really affects
4:37 the um the potential for contamination
4:40 etc that could happen. And uh just to
4:42 give you the summary of it, we achieved
4:45 overall sensitivity of 91% testing
4:47 across these species and across sampling
4:50 techniques. And likewise um for
4:54 specificity we received 203 samples most
4:58 of which were um canine um and again
5:01 across free catch systo and catheterized
5:02 most of them we did not get the data on
5:05 how they were collected so um it was
5:08 pretty much open to that of these we
5:11 kept 30 just around 34 of them I think
5:14 for actual pre-validation of the the the
5:18 or QC of the the um instrument and then
5:20 went through with 169 of these culture
5:22 negative urines. So these were actual
5:24 urines sent through directly from the
5:29 lab and um overall we had uh specificity
5:31 of 92% regardless of the sampling
5:34 technique or the um potential for any of
5:37 these pathogens. And what I'd like to
5:38 round off with is that the next step for
5:42 us really is placing these um the
5:44 verified system within vets. So we have
5:47 a limited number of spaces left for
5:49 veterinary practices who are innovative
5:52 and are looking to access um these new
5:54 technologies to be part of our
5:56 technology access partnership. So
5:58 there's a QR code on screen. If you are
6:01 part of one of these practices or you
6:02 think you know someone who might be
6:04 interested, please do scan through and
6:07 register interest. On that note, I will
6:22 >> There's a question over there. >> Yeah.
6:35 >> Okay. So, the current cost is actually
6:38 on par with culture and sensitivity. So
6:39 effectively there's no uplift for the
6:57 So we tested at the threshold. So uh the
7:00 10^ the 5 that included 10 to the 5 CFP
7:03 per mill. So below that is um not
7:05 considered an active infection in that
7:08 case. So this is representative of sort
